Frontier Business
Vision
Aiming to realize “diverse ways of well-being” in conjunction with pharmaceuticals
The “well-being” sought by patients is becoming increasingly difficult to achieve with pharmaceuticals alone, not only in the treatment of diseases but also in prevention of diseases, nursing care, and reintegration into society. In the frontier business, the Company's consolidated subsidiary FrontAct Co., Ltd. is promoting R&D and the commercialization of new healthcare solutions other than pharmaceuticals, with “mental resilience” (prevention of deterioration of neuropsychiatric disorders by early detection of their signs) and “active aging” (improvement, maintenance, and enhancement of the health of the elderly through awareness) as our main business domains.
Business Domains
Development Status of Major Programs
As of january 31, 2025
Psychiatry Neurology
Program | Summary | Region | Development status | Partnering |
---|---|---|---|---|
Digital devices for relieving BPSD | Under trial sale as a non-medical device, “Aikomi Care®” and “Aikomi DS.” We are researching and developing a DTx product that enables non-pharmacotherapy, incorporating individually optimized five sensory stimulation contents, and aiming for NHI reimbursement as an approved device. | Japan | Preparing for clinical research (medical device) |
Aikomi Ltd. |
Wearable EEG meter | Service for early detection of mental diseases by daily capture of the EEG profile with simple wearable EEG meter. We aim to develop a service that enables early detection of mental illness by grasping brain wave trends. | Japan | Product development (medical device) |
NeuroSky Co., Ltd. |
Support Program for Screening of Depression/Rating of Severity | This product is designed to detect depressive episodes caused by depression or bipolar disorder and help rate the severity of the disease by analyzing patients’ vital signs and activity data collected from wearable devices. We aim to develop a medical device. | Japan | Product development (medical device) |
Keio University, i2medical LLC |
Violet light | We aim to develop neuromodulation technology via vision with violet lights flashing at 40 Hz to treat and prevent psychiatric or neurologic illnesses. | Japan | Product development (non-medical and medical device) |
Tsubota Laboratory, Inc. |
Motor dysfunction
Program | Summary | Region | Development status | Partnering |
---|---|---|---|---|
Neurorehabilitation device for hand/fingers paralysis | Launched “MELTz®” as a medical device. We are developing Robotic neurorehabilitation device utilizing motion intention of patients with hand/fingers paralysis from electromyogram for the patients, and aim for the NHI reimbursement as an approved device. | Japan | Product development (medical device) |
- |
Training device for hand/fingers paralysis | Under development as "MELTz® Portable". We aim to develop a small and simple device that trains patients with hand/fingers paralysis using a robot that uses myoelectric signals. | Japan | Product development (medical device) |
- |
Approaches
Patient-driven
Flexible, personalized solutions that go beyond medication to improve access to care, offer additional options and diminish stigmas and isolation.
Science-minded
Leveraging our expertise in developing medications that meaningfully enhance mental health and active aging.
Solution-focused
Scouting for ideas, connecting the best scientific minds and collaborating on cutting-edge innovations to pioneer new frontiers in healthcare.
Visionary
Redefining the relationship between pharma and total wellbeing to revolutionize supportive care through empowering and convenient choices.
Global
Exploring and facilitating opportunities for exciting collaboration and inspiring business across the geographic border, starting from US, Japan, and China.